NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday an agreement with Pharma Mar to conduct BRCA1 and BRCA2 testing on patients enrolled in a clinical study for the drug firm's novel drug candidate.

Under the agreement, Myriad will conduct testing for patients in a Phase II clinical study for Pharma Mar's PM1183 drug candidate, which induces double-stranded DNA break to cause cell death. Myriad will evaluate BRCA status in patients who respond to the drug candidate.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.